A breast surgeon explains how nurses can build baseline bioimpedance screening and long-term lymphedema surveillance into clinic workflows.
News|Articles|September 10, 2026
FDA Approves Camizestrant: Key Nursing Roles in New Breast Cancer Paradigm
Author(s)Alex Biese
Fact checked by: By ONN Staff
Oncology nursing teams must navigate the clinical logistics and patient education for the newly approved, ctDNA-guided agent camizestrant.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) granted accelerated approval to the oral selective estrogen receptor degrader (SERD) camizestrant (Etcamah, AstraZeneca) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib).
Related to this article
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Brianne Whitley, CNP, of Dana-Farber, shares strategies for hot flashes, sexual health, survivorship planning, and clinical trial access for men.
Dana-Farber's Brianne Whitley, CNP, details red-flag symptoms, ER-positive biology, and why every man with breast cancer needs a genetic referral.
Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
Advertisement
Advertisement